Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 69Multiple Myeloma 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Myelodysplastic Syndromes 37Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Non-Hodgkin 33Leukemia 32Recurrence 31Lymphoma, B-Cell 30Melanoma 27Lymphoma, Large B-Cell, Diffuse 22Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hematologic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Burkitt Lymphoma 16Neoplasms 15Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Carcinoma, Renal Cell 12Head and Neck Neoplasms 11Neuroblastoma 10Leukemia, Biphenotypic, Acute 10Graft vs Host Disease 10Neoplasms, Plasma Cell 9Neoplasm Metastasis 9Colorectal Neoplasms 9Breast Neoplasms 9

Interventions

Cisplatin 21Etoposide 20Carboplatin 20Topotecan 13pembrolizumab 12durvalumab 11Paclitaxel 10Irinotecan 9Nivolumab 7Gemcitabine 7tremelimumab 6atezolizumab 6Radiotherapy 6Docetaxel 6Pemetrexed 5Ipilimumab 5Cyclophosphamide 5rovalpituzumab tesirine 4budigalimab 4Specimen Handling 4Injections 4Doxorubicin 4Bortezomib 4130-nm albumin-bound paclitaxel 4venetoclax 3talazoparib 3olaparib 3fludarabine 3etoposide phosphate 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Small Cell Lung Carcinoma × fludarabine × Clear all
NCT07509034 2026-06-05

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

National Institutes of Health Clinical Center (CC)

Phase 1 Not yet recruiting
40 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

Phase 1 Terminated
49 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡